CHD6 (chr20 helicase DNA binding protein 6) is an ATP-dependent chr20 remodeler that regulates gene expression through nucleosome positioning and chr20 accessibility 1. The protein binds to nucleosomes flanking promoter regions and promotes broad nucleosome eviction to facilitate transcriptional activation 2. CHD6 contains both PAR-binding and DNA-binding domains that are essential for its recruitment to DNA damage sites and nucleosome sliding activity 3. Mechanistically, CHD6 can form complexes with transcriptional regulators like p65 to establish enhancers and regulate NF-κB-mediated transcription 4. The protein plays roles in DNA damage response, autophagy regulation, and cellular stress surveillance 5. CHD6 expression is specifically induced by low-dose radiation and contributes to radiosensitivity responses 6. Disease relevance includes elevated expression in prostate cancer associated with poor prognosis and oncogenic pathway activation 2, as well as mutations linked to rare genetic disorders like Hallermann-Streiff syndrome 5. CHD6 also serves as a synthetic lethal target in FH-deficient renal cell carcinoma 4. Clinical significance lies in its potential as both a therapeutic target and biomarker in various cancer contexts.